Iranian Immigrant Becomes Billionaire As Her Biotech Firm’s Stock Soars
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Here's Why Everyone's Talking About Summit Therapeutics
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
Investor's Business Daily on MSN3d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
BioSpace2d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...
BioPharma Dive1d
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
STAT12d
With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in ...
Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...
Barchart on MSN4d
Up 1,123% YTD, Is It Too Late to Buy This Breakout Biotech Stock?
The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, ...